Skip to main content

Advertisement

SpringerLink
Log in

Intact expression status of RASSF1A in acute myeloid leukemia

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

As a typical tumor suppressor gene, transcriptional silencing of ras-association domain family 1, isoform A (RASSF1A) is caused by biallelic methylation or the condition that one allele is methylated and then the other allele lost by allelic loss, as second hit. RASSF1A is inactivated epigenetically and thus down-regulated in many solid tumors. In summary, for the first time, we analyzed the expression status of RASSF1A in a cohort of 56 de novo acute myeloid leukemia (AML) patients using quantitative real-time polymerase chain reaction. Results of our study indicate that patients with AML exhibited no differences in the RASSF1A gene expression comparing to normal controls. In conclusion, expression status of RASSF1A remained intact in our target samples, indicating that RASSF1A expression variation does not participate in the pathogenesis and the progression of AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497–529.

    Article  CAS  PubMed  Google Scholar 

  2. Vardiman JW, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.

    Article  CAS  PubMed  Google Scholar 

  3. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114–28.

    CAS  PubMed  Google Scholar 

  4. Ahn EY, et al. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res. 2013;11(7):748–58.

    Article  CAS  PubMed  Google Scholar 

  5. Guo C, Zhang X, Pfeifer GP. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J Biol Chem. 2011;286(8):6253–61.

    Article  CAS  PubMed  Google Scholar 

  6. Tan KO, et al. MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains. J Biol Chem. 2001;276(4):2802–7.

    Article  CAS  PubMed  Google Scholar 

  7. Vos MD, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281(8):4557–63.

    Article  CAS  PubMed  Google Scholar 

  8. Deng ZH, et al. Activator protein-1 involved in growth inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901. World J Gastroenterol. 2008;14(9):1437–43.

    Article  CAS  PubMed  Google Scholar 

  9. Dammann R, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315–9.

    Article  CAS  PubMed  Google Scholar 

  10. Agathanggelou A, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20(12):1509–18.

    Article  CAS  PubMed  Google Scholar 

  11. Harada K, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21(27):4345–9.

    Article  CAS  PubMed  Google Scholar 

  12. Wong IH, et al. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res. 2004;10(3):994–1002.

    Article  CAS  PubMed  Google Scholar 

  13. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1–2):73–87.

    Article  CAS  PubMed  Google Scholar 

  14. Barletta E, et al. Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents. Carcinogenesis. 2004;25(5):749–55.

    Article  CAS  PubMed  Google Scholar 

  15. Bennett JM, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103(4):620–5.

    Article  CAS  PubMed  Google Scholar 

  16. Dastugue N, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9(9):1491–8.

    CAS  PubMed  Google Scholar 

  17. Greenwood MJ, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47(7):1245–52.

    Article  CAS  PubMed  Google Scholar 

  18. Beillard E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17(12):2474–86.

    Article  CAS  PubMed  Google Scholar 

  19. Johan MF, et al. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129(1):60–5.

    Article  CAS  PubMed  Google Scholar 

  20. Avramouli A, et al. Methylation status of RASSF1A in patients with chronic myeloid leukemia. Leuk Res. 2009;33(8):1130–2.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang H, et al. Methylation of RASSF1A gene promoter is regulated by p53 and DAXX. FASEB J. 2013;27(1):232–42.

    Article  CAS  PubMed  Google Scholar 

  22. Florean C, et al. Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics. 2011;3(5):581–609.

    Article  CAS  PubMed  Google Scholar 

  23. Nakao M, et al. Epigenetic system: a pathway to malignancies and a therapeutic target. Int J Hematol. 2004;80(2):103–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the patients who participated in this study.

Conflict of Interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran

    Davood Zare-Abdollahi, Shamsi Safari, Abolfazl Movafagh & Mir Davood Omrani

  2. Department of Internal Medicine/Oncology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran

    Mojtaba Ghadiani

  3. Department of Community Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran

    Sahand Riazi-Isfahani

Authors
  1. Davood Zare-Abdollahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shamsi Safari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abolfazl Movafagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mojtaba Ghadiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sahand Riazi-Isfahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mir Davood Omrani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mir Davood Omrani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zare-Abdollahi, D., Safari, S., Movafagh, A. et al. Intact expression status of RASSF1A in acute myeloid leukemia. Med Oncol 31, 770 (2014). https://doi.org/10.1007/s12032-013-0770-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-013-0770-x

Keywords

Search

Navigation